Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides

NCT00108875 is registered in ClinicalTrials.gov with Julius-Maximilians University as lead sponsor.

NCT NCT00108875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00108875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Vaccination of Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer With HLA-A1, -A2 and -B35 Restricted Survivin Peptides
Lead sponsor
Julius-Maximilians University
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 30, 2003
Completion date
Not reported
Enrollment
70
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colon cancer, malignant melanoma, pancreatic cancer